Last reviewed · How we verify
GW597599
At a glance
| Generic name | GW597599 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia (PHASE2)
- Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients (PHASE2)
- Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss. (PHASE2)
- Vestipitant 28-day Tolerance Study (PHASE2)
- PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients (PHASE2)
- A Combination Therapy In Patients With Social Anxiety Disorder (PHASE2)
- A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV) (PHASE2)
- Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW597599 CI brief — competitive landscape report
- GW597599 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI